CBD for Alcohol Use Disorders: An Updated Review Highlights Preclinical Promise and Human Nuance
A major review evaluates CBD for alcohol use disorder across recent clinical literature. Emerging findings show that while preclinical models indicated reduced consumption, human trials of CBD isolate remain largely null. Clinicians and patients should…
CBD and Threat Anticipation in Alcohol Use Disorder: What a Small Randomized Trial Found
CBD alcohol use disorder randomized trial: In a randomized crossover experiment, 800 mg daily CBD did not measurably change threat-anticipation brain activity, cognitive performance, anxiety, or craving in a small non-treatment-seeking alcohol use…
Oral Semaglutide for Alcohol Use Disorder: What a New Randomized Trial Found
A phase 2 oral semaglutide alcohol use disorder randomized trial tested 50 adults with moderate to severe alcohol use disorder. The primary craving endpoint was not significantly improved, but several secondary drinking outcomes favored semaglutide.…
Endocannabinoid System & Alcohol Use Disorder: Evidence from Preclinical & Human Studies
The endocannabinoid system alcohol use disorder evidence highlights its role in regulating reward, stress, and emotional processing. Preclinical studies show cannabinoid receptor modulators reduce alcohol intake. However, human trials have shown…
GLP-1 Drugs, Semaglutide, and the Future of Alcohol Addiction Treatment
GLP-1 receptor agonists for alcohol use disorder are attracting growing scientific interest as potential tools for reducing alcohol consumption and relapse risk. This review examines preclinical evidence, observational studies, and randomized controlled…
GLP-1 therapies- an emerging approach for alcohol reduction?
A recent study found that semaglutide significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder and obesity, offering a promising new approach.
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and
Semaglutide treatment led to a 13.7 percentage point reduction in heavy drinking days compared to placebo in patients with alcohol use disorder and obesity.
Emerging Clinical Data on GLP-1 Receptor Agonists in Alcohol Use Disorder
GLP-1 receptor agonist alcohol use disorder clinical data reveals potential therapeutic effects beyond glycemic control. This emerging evidence suggests benefits in craving reduction and reward pathway modulation. Family medicine clinicians should…
GLP-1 Drugs for Alcohol Cravings: Clinical Evidence Review
Tirzepatide alcohol cravings reduction is an emerging clinical focus in addiction medicine. This review examines the evidence supporting tirzepatide's effects on alcohol use disorder. Understanding this dual GLP-1/GIP agonist's impact may improve…
Oral Semaglutide and Medicare Coverage: Expanding GLP-1 Access
Oral semaglutide Medicare coverage is expanding access to GLP-1 therapy for patients seeking weight management options. This oral formulation offers an alternative to injections, improving adherence. Understanding Medicare Part D coverage is essential…